Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.glenmarkpharma.com | |
Market Cap | 10,912.85 Cr. | |
Enterprise Value(EV) | 13,070.69 Cr. | 2021-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 36.15 | Trailing Twelve Months Ending 2021-12 |
Price-Earning Ratio (PE) | 10.70 | Trailing Twelve Months Ending 2021-12 |
Industry PE | 28.07 | Trailing Twelve Months Ending 2021-12 |
Book Value / Share | 315.45 | Trailing Twelve Months Ending 2021-12 |
Price to Book Value | 1.23 | Calculated using Price: 386.75 |
Dividend Yield | 0.65 | Period Ending 2021-03 |
No. of Shares Subscribed | 28.22 Cr. | 282,168,156 Shares |
FaceValue | 1 | |
Company Profile | ||
Glenmark Pharmaceuticals Ltd. (GPL) was incorporated in 1977. It was founded with a vision to emerge as a leading integrated research-based, global pharmaceutical company. Its branded generics business has a significant presence in markets across emerging economies including India. It is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in many countries. Glenmark’s key therapy focus areas globally are respiratory, dermatology and oncology. Its API business sells products in many countries including the US, various countries in the EU, South America and India. India is the largest market in terms of revenue for the organization. The formulations business has five manufacturing facilities; three in India and two overseas. These facilities are approved by several regulatory bodies. The facility at Baddi, Himachal Pradesh, India is also approved by MHRA and USFDA for semi-solids. The overseas facilities are situated in Brazil and the Czech Republic. While the manufacturing facility in Brazil services requirements of the Latin American region, the Czech facility services requirements of the Central Eastern Europe region. Glenmark has also invested in a dedicated R&D facility for formulations development. This R&D centre, situated near Nashik, India is engaged in developing specialty/ branded formulations for global markets. Business area of the company The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Specialty Business: Drug Discovery: Glenmark’s ground-breaking drug discovery effort is primarily focused in the areas of inflammation [asthma/COPD, rheumatoid arthritis etc.], metabolic disorders [diabetes, obesity, etc.] and pain [neuropathic pain and inflammatory pain]. Specialty Business: Formulations Business: Glenmark’s formulations business is currently organized many regions - India, Latin America, Central Eastern Europe and Semi Regulated Markets of Africa/Asia/CIS. The formulations business focuses on therapeutic areas viz. dermatology, anti-infective, respiratory, cardiac, diabetes, gynecology, CNS, and oncology. Awards
Milestone 2010
2012
2014
2015
2016
2019
2020
|
1 Day |
|
-1.98% |
1 Week |
|
-4.76% |
1 Month |
|
-9.37% |
3 Month |
|
-14.47% |
6 Month |
|
-26.98% |
1 Year |
|
-35.69% |
2 Year |
|
+9.93% |
5 Year |
|
-36.80% |
10 Year |
|
+9.81% |
9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
Return on Equity (%) | 24.33 | 18.99 | 8.79 | 27.46 | 27.31 | 16.67 | 17.21 | 13.32 | 14.81 | |
Return on Capital Employed (%) | 17.67 | 15.04 | 12.40 | 18.53 | 20.54 | 14.77 | 16.47 | 14.04 | 15.30 | |
Return on Assets (%) | 10.40 | 7.51 | 2.58 | 8.52 | 11.33 | 7.40 | 7.98 | 6.17 | 7.11 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-09* Rs. Cr. |
Shh. Funds | 2,763 | 2,983 | 1,783 | 3,630 | 4,493 | 5,163 | 5,605 | 6,071 | 7,065 | 8,661 | |
Non Curr. Liab. | 1,625 | 1,967 | 2,749 | 1,499 | 3,258 | 2,824 | 2,280 | 3,033 | 2,804 | 1,243 | |
Curr. Liab. | 2,201 | 2,949 | 3,777 | 3,999 | 2,703 | 3,288 | 4,021 | 4,126 | 4,201 | 4,784 | |
Minority Int. | 24 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 339 | |
Equity & Liab. | 6,614 | 7,912 | 8,309 | 9,128 | 10,453 | 11,275 | 11,906 | 13,229 | 14,069 | 15,027 | |
Non Curr. Assets | 2,887 | 3,150 | 2,978 | 3,224 | 3,578 | 4,286 | 5,209 | 6,425 | 6,709 | 6,953 | |
Curr. Assets | 3,727 | 4,763 | 5,331 | 5,904 | 6,875 | 6,989 | 6,697 | 6,804 | 7,360 | 8,073 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 6,614 | 7,912 | 8,309 | 9,128 | 10,453 | 11,275 | 11,906 | 13,229 | 14,069 | 15,027 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-12 Rs. Cr. TTM |
Net Sales | 4,969 | 5,945 | 6,681 | 7,562 | 9,079 | 9,074 | 9,865 | 10,641 | 10,944 | 12,146 | |
Other Income | 11 | 11 | 7 | 20 | 37 | 91 | 208 | 160 | 50 | 68 | |
Total Income | 4,980 | 5,956 | 6,688 | 7,582 | 9,117 | 9,166 | 10,074 | 10,801 | 10,994 | 12,214 | |
Total Expenditure | -3,954 | -4,854 | -5,467 | -6,125 | -7,043 | -7,459 | -8,280 | -8,943 | -8,860 | -9,765 | |
PBIDT | 1,026 | 1,102 | 1,221 | 1,457 | 2,074 | 1,707 | 1,794 | 1,858 | 2,135 | 2,448 | |
Interest | -160 | -189 | -190 | -179 | -237 | -286 | -335 | -377 | -353 | -295 | |
Depreciation | -127 | -217 | -300 | -234 | -264 | -302 | -326 | -417 | -444 | -466 | |
Taxation | -111 | -151 | -334 | -301 | -383 | -315 | -376 | -320 | -412 | -454 | |
Exceptional Items | -187 | -81 | 167 | 33 | 45 | -178 | |||||
PAT | 628 | 546 | 209 | 743 | 1,109 | 804 | 925 | 776 | 970 | 1,055 | |
Minority Interest | -8 | -3 | 0 | 0 | 0 | 0 | 0 | 0 | -35 | ||
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 620 | 542 | 210 | 743 | 1,109 | 804 | 925 | 776 | 970 | 1,020 | |
Adjusted EPS | 23 | 20 | 8 | 26 | 39 | 28 | 33 | 28 | 34 | 36 |
Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
Cash Fr. Operatn. | 804 | 648 | 854 | 482 | 345 | 657 | 1,648 | 1,324 | 1,392 | 1,131 | |
Cash Fr. Inv. | -278 | -464 | -368 | -540 | -880 | -712 | -1,013 | -699 | -784 | -675 | |
Cash Fr. Finan. | -361 | 195 | -98 | 199 | 699 | 543 | -469 | -739 | -445 | -442 | |
Net Change | 165 | 379 | 388 | 141 | 163 | 488 | 166 | -114 | 164 | 14 | |
Cash & Cash Eqvt | 320 | 605 | 795 | 764 | 857 | 1,056 | 1,233 | 936 | 1,110 | 1,138 |
Fri, 20 May 2022
Announcement under Regulation 30 (LODR)-Press Release / Media Release Glenmark Pharmaceuticals receives sANDA approval for Abiraterone Acetate Tablets USP 500 mg |
Fri, 20 May 2022
U.S. FDA Inspection At The Company''s Monroe North Carolina (USA) Facility U.S. FDA inspection at the Companys Monroe North Carolina (USA) Facility |
Fri, 20 May 2022
U.S. FDA Inspection At The Company''s Goa India Facility U.S. FDA inspection at the Companys Goa India Facility |
Wed, 25 May 2022 |
|
|
|
|
|